Frederick M Hecht

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy
    S G Deeks
    University of California, San Francisco and San Francisco General Hospital, 94110, USA
    AIDS 13:F35-43. 1999
  2. ncbi Physicians' communication with patients about adherence to HIV medication in San Francisco and Copenhagen: a qualitative study using Grounded Theory
    Toke S Barfod
    Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
    BMC Health Serv Res 6:154. 2006
  3. ncbi Lessons from an HIV transmission pair
    Frederick M Hecht
    Division of HIV/AIDS, Department of Medicine, University of California, San Francisco, CA 94110, USA
    J Infect Dis 195:1239-41. 2007
  4. ncbi Identifying the early post-HIV antibody seroconversion period
    Frederick M Hecht
    University of California, San Francisco, CA, USA
    J Infect Dis 204:526-33. 2011
  5. ncbi A piece of my mind. The CBC
    Frederick M Hecht
    JAMA 296:149-50. 2006
  6. ncbi A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection
    Frederick M Hecht
    University of California San Francisco, San Francisco, CA 94110, USA
    J Infect Dis 194:725-33. 2006
  7. ncbi Does HIV reporting by name deter testing? MESH Study Group
    F M Hecht
    Positive Health Program HIV Section, University of California at San Francisco, 94110, USA
    AIDS 14:1801-8. 2000
  8. ncbi HIV RNA level in early infection is predicted by viral load in the transmission source
    Frederick M Hecht
    HIV AIDS Division, Department of Medicine, San Francisco General Hospital, University of California, CA 94110, USA
    AIDS 24:941-5. 2010
  9. ncbi Persistence of primary drug resistance among recently HIV-1 infected adults
    Jason D Barbour
    Gladstone Institute of Virology and Immunology, San Francisco, California 94141-9100, USA
    AIDS 18:1683-9. 2004
  10. ncbi Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection
    Brian R Long
    Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, USA
    J Virol 82:4785-92. 2008

Research Grants

  1. Yoga, Health, and Meditation
    Frederick Hecht; Fiscal Year: 2004

Detail Information

Publications88

  1. ncbi HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy
    S G Deeks
    University of California, San Francisco and San Francisco General Hospital, 94110, USA
    AIDS 13:F35-43. 1999
    ..To determine the HIV RNA and CD4 cell response to both initial and salvage therapy with protease inhibitor-based therapy, and to examine the relationship between the virological response and pre-therapy characteristics...
  2. ncbi Physicians' communication with patients about adherence to HIV medication in San Francisco and Copenhagen: a qualitative study using Grounded Theory
    Toke S Barfod
    Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
    BMC Health Serv Res 6:154. 2006
    ..The objective of this study was to explore and conceptualize patterns and difficulties in physicians' work with patients' adherence to HIV medication. No previous studies on this subject have directly observed physicians' behavior...
  3. ncbi Lessons from an HIV transmission pair
    Frederick M Hecht
    Division of HIV/AIDS, Department of Medicine, University of California, San Francisco, CA 94110, USA
    J Infect Dis 195:1239-41. 2007
  4. ncbi Identifying the early post-HIV antibody seroconversion period
    Frederick M Hecht
    University of California, San Francisco, CA, USA
    J Infect Dis 204:526-33. 2011
    ..Identifying persons with recent human immunodeficiency virus (HIV) antibody seroconversion is useful for treatment, research, and prevention, but the sensitivity and specificity of tests for this purpose are uncertain...
  5. ncbi A piece of my mind. The CBC
    Frederick M Hecht
    JAMA 296:149-50. 2006
  6. ncbi A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection
    Frederick M Hecht
    University of California San Francisco, San Francisco, CA 94110, USA
    J Infect Dis 194:725-33. 2006
    ....
  7. ncbi Does HIV reporting by name deter testing? MESH Study Group
    F M Hecht
    Positive Health Program HIV Section, University of California at San Francisco, 94110, USA
    AIDS 14:1801-8. 2000
    ..We sought to determine whether persons at risk of HIV infection knew their state's HIV reporting policy and whether they had delayed or avoided testing because of it...
  8. ncbi HIV RNA level in early infection is predicted by viral load in the transmission source
    Frederick M Hecht
    HIV AIDS Division, Department of Medicine, San Francisco General Hospital, University of California, CA 94110, USA
    AIDS 24:941-5. 2010
    ..We sought to determine the relationship between HIV-1 RNA levels in the source partner and recently infected recipient partners within transmission pairs...
  9. ncbi Persistence of primary drug resistance among recently HIV-1 infected adults
    Jason D Barbour
    Gladstone Institute of Virology and Immunology, San Francisco, California 94141-9100, USA
    AIDS 18:1683-9. 2004
    ..Surveillance and clinical detection of primary resistance is feasible in the first year of infection...
  10. ncbi Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection
    Brian R Long
    Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, USA
    J Virol 82:4785-92. 2008
    ....
  11. ncbi Rapid progressing allele HLA-B35 Px restricted anti-HIV-1 CD8+ T cells recognize vestigial CTL epitopes
    Christian B Willberg
    Division of Experimental Medicine, Department of Medicine, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 5:e10249. 2010
    ..The HLA-B*35-Px allele has been associated with rapid disease progression in HIV-1 infection, in contrast to the HLA-B*35-Py allele...
  12. ncbi Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity
    Jason D Barbour
    Positive Health Program, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California, USA
    AIDS 20:2123-5. 2006
    ..Viral polRC was measured before starting ART in all subjects. We examined 243 individuals for a median 260 days after initiating ART. Low baseline polRC was associated with greater CD4 T-cell gains independent of virological responses...
  13. ncbi CD8+ cell anti-HIV activity rapidly increases upon discontinuation of early antiretroviral therapy
    M Scott Killian
    Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA
    J Clin Immunol 29:311-8. 2009
    ..CD8+ lymphocytes can suppress HIV replication without killing the infected cells. This CD8+ cell noncytotoxic anti-HIV response (CNAR) is associated with a beneficial clinical course...
  14. ncbi Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape
    Annika C Karlsson
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, California, United States of America
    PLoS ONE 2:e225. 2007
    ....
  15. ncbi T cell responses to human endogenous retroviruses in HIV-1 infection
    Keith E Garrison
    Division of Experimental Medicine, Department of Medicine, University of California San Francisco, San Francisco, California, United States of America
    PLoS Pathog 3:e165. 2007
    ..HERV-specific immunity is an important new avenue for investigation in HIV-1 pathogenesis and vaccine design...
  16. ncbi The effects of early antiretroviral therapy and its discontinuation on the HIV-specific antibody response
    M Scott Killian
    Department of Medicine, University of California San Francisco, 94143, USA
    AIDS Res Hum Retroviruses 22:640-7. 2006
    ..These results demonstrate that early ART prevents the typical evolution of the HIV-1-specific antibody response and can alter the expected kinetics of this response in subjects discontinuing therapy...
  17. ncbi Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load
    Steven G Deeks
    San Francisco General Hospital, 995 Potrero Ave, San Francisco, CA 94110, USA
    Blood 104:942-7. 2004
    ..These data indicate that immunologic activation set point is established early in HIV infection, and that this set point determines the rate at which CD4+ T cells are lost over time...
  18. ncbi Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses
    Steven G Deeks
    Department of Medicine, University of California at San Francisco, San Francisco General Hospital, CA 94110, USA
    J Virol 80:6155-64. 2006
    ..These observations also suggest that the neutralizing antibody response may contribute to the long-term control of HIV in some patients while protecting against HIV superinfection in most patients...
  19. ncbi Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection
    Jason D Barbour
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, USA
    J Infect Dis 190:251-6. 2004
    ..The pol RC value of 43% may represent a threshold below which HIV-1 has lowered virulence and is less able to deplete CD4(+) T cell counts...
  20. ncbi High CD8+ T cell activation marks a less differentiated HIV-1 specific CD8+ T cell response that is not altered by suppression of viral replication
    Jason D Barbour
    Department of Medicine, HIV AIDS Division, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 4:e4408. 2009
    ..We hypothesized that anti-retroviral suppression of T cell activation levels would lead to alterations in the T cell differentiation of total and HIV-1 specific CD8+ T cell responses among recently HIV-1 infected adults...
  21. ncbi Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection
    C Bradley Hare
    Positive Health Program, University of California, San Francisco, San Francisco, CA, USA
    Clin Infect Dis 42:700-8. 2006
    ....
  22. ncbi Similar changes in plasmacytoid dendritic cell and CD4 T-cell counts during primary HIV-1 infection and treatment
    M Scott Killian
    Department of Medicine, University of California-San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA
    AIDS 20:1247-52. 2006
    ..Early ART appears to have similar restorative effects on pDC and CD4 T-cell counts...
  23. ncbi Differential persistence of transmitted HIV-1 drug resistance mutation classes
    Vivek Jain
    HIV AIDS Division, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA 94143, USA
    J Infect Dis 203:1174-81. 2011
    ..The impact of class-specific mutations on this rate of mutation replacement is uncertain...
  24. ncbi FOXP3 expressing CD127lo CD4+ T cells inversely correlate with CD38+ CD8+ T cell activation levels in primary HIV-1 infection
    Lishomwa C Ndhlovu
    Division of Experimental Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA 94110, USA
    J Leukoc Biol 83:254-62. 2008
    ....
  25. ncbi The relation between symptoms, viral load, and viral load set point in primary HIV infection
    Colleen F Kelley
    Department of Medicine, San Francisco General Hospital, University of California at San Francisco, 995 Potrero Avenue, San Francisco, CA 94110, USA
    J Acquir Immune Defic Syndr 45:445-8. 2007
    ..To examine the relation between symptoms, initial viral load, and viral load set point in primary HIV infection (PHI)...
  26. ncbi HIV disease progression correlates with the generation of dysfunctional naive CD8(low) T cells
    David Favre
    Division of Experimental Medicine, University of California at San Francisco, San Francisco, CA, USA
    Blood 117:2189-99. 2011
    ..This study is registered at www.clinicaltrials.gov as NCT00187512...
  27. ncbi Expansion of CD8+ T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity
    Emily M Eriksson
    Division of Experimental Medicine, Department of Medicine, University of California San Francisco, USA
    Blood 119:745-55. 2012
    ..These data suggest that loss of CD100 expression probably plays an important role in dysfunctional immunity in HIV-1 infection...
  28. ncbi Lower cytokine secretion ex vivo by natural killer T cells in HIV-infected individuals is associated with higher CD161 expression
    Jennifer E Snyder-Cappione
    Division of Experimental Medicine, Department of Medicine, University of California San Francisco, 1001 Potrero Avenue, San Francisco, CA 94110, USA
    AIDS 23:1965-70. 2009
    ..This study measured NKT cell cytokine production directly ex vivo and compared these responses with both the disease status and NKT subset distribution of individual patients...
  29. ncbi Strong human endogenous retrovirus-specific T cell responses are associated with control of HIV-1 in chronic infection
    Devi SenGupta
    UCSF Division of Experimental Medicine, Building 3, Room 603, San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, CA 94110, USA
    J Virol 85:6977-85. 2011
    ..These findings suggest a possible role for anti-HERV immunity in the control of chronic HIV-1 infection and provide support for a larger effort to design an HIV-1 vaccine that targets conserved antigens such as HERV...
  30. ncbi HIV-1-specific T Cell-dependent natural killer (NK) cell activation: major contribution by NK cells to interferon-gamma production in response to HIV-1 antigens
    Christopher P Loo
    Division of Experimental Medicine, Department of Medicine, University of California San Francisco, San Francisco, California, USA
    AIDS Res Hum Retroviruses 25:603-5. 2009
    ..These results indicate that T cell-dependent NK cell IFN-gamma production can be important for immune control of HIV-1, and have implications for the interpretation of data from vaccine trials using ELISPOT and ELISA...
  31. ncbi Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009
    Vivek Jain
    HIV AIDS Division, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 5:e15510. 2010
    ..Although several new HIV medications were introduced starting in late 2007, including raltegravir, maraviroc, and etravirine, it is not known whether the prevalence of TDR was subsequently affected in 2008-2009...
  32. ncbi Transcriptional errors in human immunodeficiency virus type 1 generate targets for T-cell responses
    Keith E Garrison
    Division of Experimental Medicine, Department of Medicine, UCSF, San Francisco, California 94110, USA
    Clin Vaccine Immunol 16:1369-71. 2009
    ..T-cell responses to cryptic epitopes and to regions normally spliced out of the HIV-1 viral proteins Rev and Tat were detected in HIV-1-infected subjects...
  33. ncbi Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease
    David Favre
    Division of Experimental Medicine, Department of Medicine, University of California, San Francisco, CA 94110, USA
    Sci Transl Med 2:32ra36. 2010
    ..We postulate that induction of IDO may represent a critical initiating event that results in inversion of the T(H)17/T(reg) balance and in the consequent maintenance of a chronic inflammatory state in progressive HIV disease...
  34. ncbi Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance
    Grant Nash Colfax
    AIDS Office, San Francisco Department of Public Health, San Francisco, California, USA
    AIDS 21:239-41. 2007
    ..We postulate that this association may be caused by methamphetamine-associated treatment interruptions among source partners...
  35. ncbi IL-2 immunotherapy to recently HIV-1 infected adults maintains the numbers of IL-17 expressing CD4+ T (T(H)17) cells in the periphery
    Lishomwa C Ndhlovu
    Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA
    J Clin Immunol 30:681-92. 2010
    ..However, IL-2-mediated T-reg expansions may selectively reduce responses to certain antigen-specific populations, such as HIV-1 Gag...
  36. ncbi Time trends in primary HIV-1 drug resistance among recently infected persons
    Robert M Grant
    Gladstone Institute of Virology and Immunology, PO Box 914100, San Francisco, CA 94141, USA
    JAMA 288:181-8. 2002
    ..Transmission of multiclass drug-resistant human immunodeficiency virus type 1 (HIV-1) may increase with wider use of antiretroviral therapy...
  37. ncbi Interleukin-2 therapy restores CD8 cell non-cytotoxic anti-HIV responses in primary infection subjects receiving HAART
    Beatriz Martinez-Mariño
    Department of Medicine, University of California, San Francisco, San Francisco, CA 94143 1270, USA
    AIDS 18:1991-9. 2004
    ..To determine the effect of interleukin-2 (IL-2) therapy on immunologic and virologic responses in subjects with acute or recent HIV infection already receiving highly active antiretroviral therapy (HAART)...
  38. ncbi Use of laboratory tests and clinical symptoms for identification of primary HIV infection
    Frederick M Hecht
    Positive Health Program HIV Section at San Francisco General Hospital, tUniversity of California at San Francisco, 94110, USA
    AIDS 16:1119-29. 2002
    ..False-positive results can be reduced through duplicate testing and considering tests < 5000 copies/ml as indeterminate results requiring additional testing. p24 antigen was more specific than HIV-1 RNA testing but less sensitive...
  39. ncbi Loss of T cell responses following long-term cryopreservation
    Rachel E Owen
    Blood Systems Research Institute, 270 Masonic Avenue, San Francisco, CA 94118, USA
    J Immunol Methods 326:93-115. 2007
    ..Long-term cryopreservation, however, may lead to the loss of CD4(+) T cell responses and mild skewing of T cell phenotypic marker expression...
  40. ncbi Elevated frequency of gamma interferon-producing NK cells in healthy adults vaccinated against influenza virus
    Brian R Long
    Division of Experimental Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California 941101, USA
    Clin Vaccine Immunol 15:120-30. 2008
    ..These results may form the basis for further investigations of the role of NK cells in immunity to influenza...
  41. ncbi Stimulant use is associated with immune activation and depleted tryptophan among HIV-positive persons on anti-retroviral therapy
    Adam W Carrico
    Center for AIDS Prevention Studies, University of California, San Francisco, 50 Beale Street, Suite 1300, San Francisco, CA 94105, USA
    Brain Behav Immun 22:1257-62. 2008
    ..Further research is needed to replicate these findings and examine the plausible bio-behavioral pathways that may account for the effects of stimulant use on HIV disease markers and depleted tryptophan...
  42. ncbi Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden
    Serena Spudich
    Department of Neurology, University of California San Francisco, USA
    J Infect Dis 204:753-60. 2011
    ..Although HIV enters the nervous system soon after transmission, the magnitude of infection and immunoactivation within the CNS during primary HIV infection (PHI) has not been characterized...
  43. ncbi Increased HLA-DR expression on peripheral blood monocytes in subsets of subjects with primary HIV infection is associated with elevated CD4 T-cell apoptosis and CD4 T-cell depletion
    Ronnie L Gascon
    University of California at San Francisco, Department of Medicine, 94110, USA
    J Acquir Immune Defic Syndr 30:146-53. 2002
    ..002). We conclude that monocyte activation as defined by elevation of CD14/DR expression correlates to CD4 T-cell depletion in primary HIV infection, and is predictive of a poor CD4 T-cell response to HAART in a subset of patients...
  44. ncbi Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection
    S A Stranford
    Department of Medicine, University of California, San Francisco, CA 94143; Blood Centers of the Pacific, San Francisco, CA 94118, USA
    Proc Natl Acad Sci U S A 98:597-602. 2001
    ....
  45. ncbi Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection
    Philip J Norris
    Blood Systems Research Institute, San Francisco, California 94118, USA
    AIDS Res Hum Retroviruses 22:757-62. 2006
    ..Cytokine alterations occurred within 7 days of detectable HIV-1 viremia, emphasizing the need to study the earliest events of infection...
  46. ncbi Synergy or independence? Deciphering the interaction of HLA Class I and NK cell KIR alleles in early HIV-1 disease progression
    Jason D Barbour
    HIV AIDS Division, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America
    PLoS Pathog 3:e43. 2007
  47. ncbi Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy
    Mark A Jacobson
    Positive Health Program, Department of Medicine, University of California, San Francisco, USA
    AIDS 17:917-9. 2003
  48. ncbi Effect of IL-2 therapy on CD8+ cell noncytotoxic anti-HIV response during primary HIV-1 infection
    B Martinez-Marino
    Department of Medicine, University of California, San Francisco, USA
    J Clin Immunol 24:135-44. 2004
    ..The first cycle of IL-2 enhanced CNAR; later cycles showed no substantial effect. This study suggests that HAART combined with IL-2 could provide an immunologic benefit in the treatment of early HIV infection...
  49. ncbi Differential expression of CD96 surface molecule represents CD8⁺ T cells with dissimilar effector function during HIV-1 infection
    Emily M Eriksson
    Division of Experimental Medicine, Department of Medicine, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 7:e51696. 2012
    ..Overall, these findings indicate that down-regulation of CD96 is an important aspect of HIV-1 pathogenesis and differential expression is related to cell effector functions and HIV-1 disease course...
  50. ncbi The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease
    Jennifer E Ho
    Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA
    AIDS 26:1115-20. 2012
    ..HIV-infected individuals are at high risk of developing cardiovascular disease. Whether earlier initiation of HIV therapy at higher CD4 cell counts has any effect on cardiovascular risk as assessed by endothelial function is unknown...
  51. ncbi Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection
    Bhupat D Rawal
    Blood Centers of the Pacific, San Francisco, California 94118, USA
    J Acquir Immune Defic Syndr 33:349-55. 2003
    ..These results support the potential use of the Vironostika-LS EIA for detection of recent HIV-1 infections for incidence projections and for other epidemiologic, clinical, and molecular surveillance applications...
  52. ncbi Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals
    Jennifer E Ho
    Division of Cardiology, San Francisco General Hospital, San Francisco, California 94110, USA
    AIDS 24:1897-905. 2010
    ..HIV infection is associated with increased rates of cardiovascular disease. We sought to evaluate whether initiation of HIV therapy at higher nadir CD4(+) T-cell counts might reduce cardiovascular risk, as measured by arterial stiffness...
  53. ncbi Body awareness: construct and self-report measures
    Wolf E Mehling
    Osher Center for Integrative Medicine, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 4:e5614. 2009
    ..We assessed the psychometric quality of selected self-report measures and examined their items for underlying definitions of the construct...
  54. ncbi Symptom management with massage and acupuncture in postoperative cancer patients: a randomized controlled trial
    Wolf E Mehling
    Osher Center for Integrative Medicine, and Department of Epidemiology and Biostatistics, University of California, San Francisco, California 94115, USA
    J Pain Symptom Manage 33:258-66. 2007
    ..These findings merit independent confirmation using larger sample sizes and attention control...
  55. ncbi Seroconversion following nonoccupational postexposure prophylaxis against HIV
    Michelle E Roland
    Positive Health Program at San Francisco General Hospital, California, USA
    Clin Infect Dis 41:1507-13. 2005
    ..We sought to describe the occurrence and circumstances of HIV seroconversion following nonoccupational PEP...
  56. ncbi Provider assessment of adherence to HIV antiretroviral therapy
    D R Bangsberg
    Epidemiology and Prevention Interventions Center, Division of Infectious Diseases and the Positive Health Program, San Francisco General Hospital University of California, San Francisco UCSF 94110, USA
    J Acquir Immune Defic Syndr 26:435-42. 2001
    ..Adherence assessment is an essential component of monitoring HIV antiretroviral therapy. Prior studies suggest that medical providers frequently estimate individual patient adherence inaccurately...
  57. ncbi Optimizing care for persons with HIV infection. Society of General Internal Medicine AIDS Task Force
    F M Hecht
    San Francisco General Hospital, University of California, San Francisco, AIDS Program, 94143 0874, USA
    Ann Intern Med 131:136-43. 1999
    ..Primary care physicians need to strengthen these basic HIV-related medical skills...
  58. ncbi Name-based surveillance and public health interventions for persons with HIV infection. Multistate Evaluation of Surveillance for HIV Study Group
    D H Osmond
    Department of Epidemiology and Biostatistics, University of California, San Francisco 94143, USA
    Ann Intern Med 131:775-9. 1999
    ..These results suggest that the potential for such effects has been exaggerated...
  59. ncbi Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5
    T Elbeik
    Departments of Laboratory Medicine, University of California, San Francisco, USA
    J Clin Microbiol 38:1113-20. 2000
    ..5 assay. Moreover, cost analysis based on labor, disposables, and biohazardous wastes showed significant savings with the bDNA 3.0 assay as compared to the costs of the Amplicor 1.5 assay...
  60. ncbi Multistate evaluation of anonymous HIV testing and access to medical care. Multistate Evaluation of Surveillance of HIV (MESH) Study Group
    A B Bindman
    Primary Care Research Center, San Francisco General Hospital, and Department of Medicine, University of California, 94110, USA
    JAMA 280:1416-20. 1998
    ..Infection with the human immunodeficiency virus (HIV) is the only infectious disease for which anonymous testing is publicly funded, an exception that has been controversial...
  61. ncbi Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
    D R Bangsberg
    Epidemiology and Prevention Interventions Center, Division of Infectious Diseases, San Francisco General Hospital, University of California San Francisco, 94110, USA
    AIDS 14:357-66. 2000
    ..To examine the relationship between adherence, viral suppression and antiretroviral resistance in HIV-infected homeless and marginally housed people on protease inhibitor (PI) therapy...
  62. ncbi Changes in stress, eating, and metabolic factors are related to changes in telomerase activity in a randomized mindfulness intervention pilot study
    JENNIFER DAUBENMIER
    Osher Center for Integrative Medicine, Department of Medicine, University of California, San Francisco, CA, USA
    Psychoneuroendocrinology 37:917-28. 2012
    ....
  63. ncbi Mindfulness-based stress reduction for HIV treatment side effects: a randomized, wait-list controlled trial
    Larissa G Duncan
    Osher Center for Integrative Medicine, University of California at San Francisco School of Medicine, San Francisco, California, USA
    J Pain Symptom Manage 43:161-71. 2012
    ..Advances in antiretroviral therapy (ART) for HIV offer life-extending benefit; however, the side effects associated with ART use negatively impact quality of life and medication adherence among people living with HIV...
  64. ncbi The detection of acute HIV infection
    Myron S Cohen
    Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7030, USA
    J Infect Dis 202:S270-7. 2010
    ..We conclude that further technical advances are essential to allow more widespread detection of patients with AHI and to affect HIV treatment outcomes and transmission prevention...
  65. ncbi Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens
    Einar M Aandahl
    Gladstone Institute of Virology and Immunology, University of California San Francisco, San Francisco, California 94110, USA
    J Virol 78:2454-9. 2004
    ..We propose that chronic viral infections lead to induction of suppressive T(R) cells that inhibit the antiviral immune response...
  66. ncbi What happened to home HIV test collection kits? Intent to use kits, actual use, and barriers to use among persons at risk for HIV infection
    G N Colfax
    HIV Research Branch, San Francisco Department of Public Health, 25 Van Ness Avenue, Suite 500, San Francisco, CA 94102 6033, USA
    AIDS Care 14:675-82. 2002
    ..Increasing awareness of kits, reducing price and addressing concerns about kit testing procedures may increase kit use, leading to more HIV testing by at-risk individuals...
  67. ncbi Yoga breathing for cancer chemotherapy-associated symptoms and quality of life: results of a pilot randomized controlled trial
    Anand Dhruva
    Osher Center for Integrative Medicine, University of California, San Francisco, San Francisco, CA 94143, USA
    J Altern Complement Med 18:473-9. 2012
    ..Pranayama, a series of yogic breathing techniques, may improve cancer-related symptoms and quality of life, but it has not been studied for this purpose...
  68. ncbi The calm mouse: an animal model of stress reduction
    Blake T Gurfein
    Osher Center for Integrative Medicine, University of California, San Francisco, California, United States of America
    Mol Med 18:606-17. 2012
    ..Together, our results suggest that the Calm mouse model represents a promising approach to studying the biological effects of stress reduction in the context of health and in conjunction with existing disease models...
  69. ncbi Longitudinal analysis of B cell repertoire and antibody gene rearrangements during early HIV infection
    M K Elkins
    Department of Neurology, University of California at San Francisco, CA 94143-0435, USA
    Genes Immun 6:66-9. 2005
    ..A modest association between B cell repertoire integrity and viremia levels as well as treatment was detected...
  70. ncbi Antiretroviral drug therapy alters the profile of human immunodeficiency virus type 1-specific T-cell responses and shifts the immunodominant cytotoxic T-lymphocyte response from Gag to Pol
    A C Karlsson
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, California 94141, USA
    J Virol 81:11543-8. 2007
    ..The consequences of dual pressures from treatment and CTL need to be considered in monitoring of drug therapy...
  71. ncbi Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo
    Erik S Zimmerman
    Division of Cellular Biology and Immunology, Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah 84132, USA
    J Virol 80:10407-18. 2006
    ..We report that infected cells in vivo display an aberrant cell cycle profile whereby a majority of cells have a 4N DNA content, consistent with the onset of G2 arrest...
  72. ncbi Potential herpesvirus interaction during HIV type 1 primary infection
    Evelyne T Lennette
    Nectandra Institute, San Ramon, Costa Rica
    AIDS Res Hum Retroviruses 21:869-75. 2005
    ..uninfected individuals. Notably, lower HIV-1 viremia (7,313 vs. 55,548 geometric mean RNA copies/ml) at baseline was significantly associated with HHV-8 seropositivity (p < 0.004)...
  73. ncbi Nucleic acid amplification testing for diagnosis of acute HIV infection: has the time come?
    Michael P Busch
    AIDS 19:1317-9. 2005
  74. ncbi Microbial translocation is a cause of systemic immune activation in chronic HIV infection
    Jason M Brenchley
    Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 12:1365-71. 2006
    ..These data establish a mechanism for chronic immune activation in the context of a compromised gastrointestinal mucosal surface and provide new directions for therapeutic interventions that modify the consequences of acute HIV infection...
  75. ncbi Expansion of CD7(low) and CD7(negative) CD8 T-cell effector subsets in HIV-1 infection: correlation with antigenic load and reversion by antiretroviral treatment
    Einar M Aandahl
    The Biotechnology Centre of Oslo, University of Oslo, Norway
    Blood 104:3672-8. 2004
    ..The results are discussed in relation to the dual roles of CD7 as a receptor of both costimulation and cell death...
  76. ncbi Expansion of CD1d-restricted NKT cells in patients with primary HIV-1 infection treated with interleukin-2
    Markus Moll
    CIM, Department of Medicine, F59, Karolinska Institute, Karolinska University Hospital, Huddinge, 14186 Stockholm, Sweden
    Blood 107:3081-3. 2006
    ..These data indicate that IL-2 treatment in combination with effective ART is beneficial for the restoration of innate NKT cell immunity in patients with primary HIV-1 infection...
  77. ncbi Human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T(EMRA) cells in early infection are linked to control of HIV-1 viremia and predict the subsequent viral load set point
    John W Northfield
    Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, South Parks Road, Oxford OX1 3SY, United Kingdom
    J Virol 81:5759-65. 2007
    ....
  78. ncbi Quantitative longitudinal analysis of T cell receptor repertoire expression in HIV-infected patients on antiretroviral and interleukin-2 therapy
    Uma Sriram
    Department of Neurology University of California at San Francisco, California 94143, USA
    AIDS Res Hum Retroviruses 23:741-7. 2007
    ..These results suggest that homeostasis in the T cell receptor repertoire is more robust in those patients who stay on HAART for a long time and confirm the polyclonal stimulating capacity of IL-2...
  79. ncbi CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms
    Matthew J Dolan
    Infectious Disease Clinical Research Program, Wilford Hall United States Air Force Medical Center, Lackland Air Force Base, Texas 78236, USA
    Nat Immunol 8:1324-36. 2007
    ..These results identify CCL3L1 and CCR5 as major determinants of CMI and demonstrate that these host factors influence HIV pathogenesis through their effects on both CMI and other viral entry-independent mechanisms...
  80. ncbi HIV testing within at-risk populations in the United States and the reasons for seeking or avoiding HIV testing
    Scott E Kellerman
    National Center for HIV, STD, and TB Prevention, Division of HIV AIDS Prevention Surveillance and Epidemiology, Surveillance Branch, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Acquir Immune Defic Syndr 31:202-10. 2002
    ..We determined proportions of high-risk persons tested for HIV, the reasons for testing and not testing, and attitudes and perceptions regarding HIV testing, information that is critical for planning prevention programs...
  81. ncbi Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection
    Marcus Altfeld
    Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital, Boston, Massachusetts, USA
    AIDS 17:2581-91. 2003
    ..CONCLUSION: These data demonstrate that host genetic factors can influence the clinical manifestations of acute HIV-1 infection and provide a functional link between HLA-B57 and viral immune control...
  82. ncbi Immune reconstitution of CD56(dim) NK cells in individuals with primary HIV-1 infection treated with interleukin-2
    Jakob Michaelsson
    Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    J Infect Dis 197:117-25. 2008
    ..Importantly, NK cell receptor expression and IFN-gamma production were maintained over time. This reconstitution of NK cells may be useful in helping contain viremia if patients discontinue therapy or develop drug resistance...
  83. ncbi CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals
    Sunil K Ahuja
    Veterans Administration Research Center for AIDS and HIV 1 Infection, South Texas Veterans Health Care System, 7400 Merton Minter, San Antonio, Texas 78229, USA
    Nat Med 14:413-20. 2008
    ..Furthermore, as reconstitution of CD4(+) cells during HAART is more sensitive to CCL3L1 dose than to CCR5 genotypes, CCL3L1 analogs might be efficacious in supporting immunological reconstitution...
  84. ncbi Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance
    Lin Liu
    University of California San Diego, La Jolla, California 92093 0679, USA
    AIDS 22:835-9. 2008
    ..We compared eight genotypic interpretation methods to determine whether the method used would affect the rates of reported transmitted drug resistance...
  85. ncbi Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion
    Don E Smith
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2010, Australia
    AIDS Res Hum Retroviruses 19:189-99. 2003
    ..Despite poorer prognostic markers at baseline ES subjects achieved responses similar to those of LS subjects after 1 year of treatment...
  86. ncbi Changes in HIV testing after implementation of name-based HIV case surveillance in New Mexico
    Amy Lansky
    Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Am J Public Health 92:1757. 2002
  87. ncbi Resistance testing in drug-naive HIV-infected patients: is it time?
    Frederick M Hecht
    Clin Infect Dis 41:1324-5. 2005
  88. ncbi Newly diagnosed HIV infection
    Peter V Chin-Hong
    N Engl J Med 354:771-2; author reply 771-2. 2006

Research Grants4

  1. Yoga, Health, and Meditation
    Frederick Hecht; Fiscal Year: 2004
    ..abstract_text> ..